Skip to content

TNFSF14 (LIGHT) as a Gout Target

TNFSF14 — also known as LIGHT (homologous to lymphotoxins, inducible, competes with HSV glycoprotein D for HVEM) — is a TNF-superfamily cytokine produced by activated monocytes, macrophages, neutrophils, B cells, and T cells. Ea et al. 2024 identified it as the second-highest fold-change inflammatory biomarker in gout flare, after IL-6, across two independent cohorts. Ex vivo blockade of TNFSF14 reduced LPS+MSU-induced cytokine response. This page synthesizes the evidence for TNFSF14 as a gout-relevant therapeutic target and its placement in the NLRP3 chokepoint framework.

1. The seed finding (Clinical + In Vitro)

Ea et al. Ann Rheum Dis 2024 (PMID: 38373842) used the Olink 92-protein inflammation panel on the prospective GOUTROS cohort, sampling at three timepoints: T1 (flare), T2 (intercritical), T3 (after reaching serum urate target under urate-lowering therapy). Validation in an independent cohort (OLT1177-05 — the dapansutrile Phase 2a patients, T1 and T2 only).

  • 21 proteins differentially expressed across phases
  • Four elevated at flare vs. intercritical in both cohorts: IL-6, CSF1 (M-CSF), VEGF-A, TNFSF14
  • IL-6 and TNFSF14 showed the highest fold change at T1
  • TNFSF14 was produced at the inflamed joint (local myeloid source, not systemic spillover alone)
  • Recombinant TNFSF14 enhanced LPS+MSU ex vivo cytokine production; anti-TNFSF14 blockade reduced it
  • TNFSF14 SNPs modulated myeloid cytokine output — genetic dose-response

Sample sizes and exact statistical thresholds are in the full text (not retrievable via PMC at the time of this audit — retrieve the PDF for Pass-2 quantitative extraction).

2. Mechanism: a parallel NF-κB amplifier, not a new sensor

No PubMed paper links TNFSF14 directly to NLRP3 assembly, ASC speck formation, caspase-1 cleavage, or gasdermin D pore formation (zero hits on "TNFSF14 NLRP3 inflammasome" or "TNFSF14 inflammasome"). TNFSF14 is not a CP2 / CP3 / CP4 / CP6 exploit.

TNFSF14 instead binds two receptors:

  • HVEM (TNFRSF14) — on lymphocytes and myeloid cells; also binds BTLA (inhibitory) and CD160
  • LTβR (lymphotoxin β receptor) — on stromal cells, synoviocytes, myeloid cells, epithelium; also binds LTα1β2

Downstream signaling activates canonical NF-κB, non-canonical NF-κB (NIK/RelB), JNK/AP-1, and p38 MAPK — the same transcription factors that generate pro-IL-1β and NLRP3 transcripts during classical LPS/DAMP priming. This places TNFSF14 squarely within CP1 (priming), as a myeloid-autocrine / paracrine amplifier loop layered on top of LPS/TLR4 and DAMP/NLR priming.

  • Zhong et al. 2020 J Cell Mol Med (PMID: 32881263): LIGHT → TLR4-MyD88-NF-κB axis in sepsis-associated AKI. LIGHT KO attenuates LPS injury; HVEM-Fc and LTβR-Fc rescue wild-type mice. (Animal Model + In Vitro.)
  • Lai et al. 2023 Mediators Inflamm (PMID: 36654880): TLR3 agonist poly(I:C) induces LIGHT via NF-κB; LIGHT then amplifies NF-κB further. Classic feed-forward. Soluble HVEM ameliorates liver injury. (Animal Model.)
  • Herrero-Cervera et al. Diabetologia 2019 (PMID: 31388695): LIGHT-deficient mice on high-fat/high-cholesterol diet have improved glucose tolerance, less hepatic steatosis, reduced systemic TNF-α and IL-6, fewer F4/80+CD11c+ pro-inflammatory adipose macrophages. (Animal Model.)

3. Gout-relevant cell types express both receptors

  • Fibroblast-like synoviocytes (FLS): Ishida et al. 2008 (PMID: 18412315) — FLS from RA synovium express HVEM and LTβR; LIGHT stimulation drives MMP-9/12, IL-8, MCP-1, MIP-1α, ICAM-1 via LTβR (not HVEM) and NF-κB. LIGHT synovial-fluid levels are elevated in RA vs. OA. Mechanistic extrapolation to gouty synovitis: MSU deposits activate the same synovial tissue, and the same ligand–receptor system is present.
  • Osteoclastogenesis: Ishida et al. 2008 Immunology (PMID: 19019090) — LIGHT promotes osteoclast differentiation from CD14+ monocytes co-cultured with synovial nurse-like cells, synergizing with RANKL. Relevant to long-term joint damage in chronic tophaceous gout.
  • B cells + monocytes: Kang et al. 2007 Arthritis Rheum (PMID: 17393389) — in RA, LIGHT is upregulated on CD20+ B cells and monocytes. Produced centrally by both innate and adaptive arms.
  • Myeloid cells in colitis: Krause et al. 2014 Gastroenterology (PMID: 24560868); Giles et al. 2018 Front Immunol (PMID: 30524422) — LIGHT signaling through LTβR drives both inflammation and resolution context-dependently. Full KO worsens colitis. This is a caution flag for total-body blockade.
  • Psoriatic keratinocytes: Ye et al. 2026 (PMID: 41684072) — HaCaT cells express HVEM and LTβR; LIGHT drives IL-6, IL-8, PGI2, PTGS2 via JNK/AP-1-HVEM-LIGHT pathway. Extends the cell-type reach.

4. Therapeutic landscape

Clinical

  • CERC-002 (Avalo Therapeutics, formerly Cerecor): humanized anti-LIGHT mAb. Phase 2 RCT in COVID-19 ARDS (NCT04412057, N=83), J Clin Invest 2022 (PMID: 34871182). 83.9% (CERC-002) vs. 64.5% (placebo) alive and respiratory-failure-free at day 28 (p=0.044); mortality 7.7% vs. 14.3%. Clinical Trial — positive Phase 2 in a different indication. No gout trial on record. Avalo has pursued CERC-002 in additional indications including pyoderma gangrenosum, GvHD, and IBD. Joosten's Radboud group co-authored Ea 2024 and the dapansutrile Phase 2a — they have the gout cohorts and the relationship with the NLRP3-ARDS clinical world.
  • Historical LTβR fusion protein: baminercept (Biogen) — LTβR-Fc, tested in RA (did not meet primary endpoint) and Sjögren's. Programs paused. Preclinical utility still demonstrated (Zhong 2020 with LTβR-Fc rescue).

Natural compounds with published direct TNFSF14 activity

  • EGCG, ECG, theaflavin-3,3'-digallate (green and black tea polyphenols): Hosokawa et al. 2010 Mol Nutr Food Res (PMID: 20461739) — suppress TNFSF14-induced IL-6 in human gingival fibroblasts; block TNFSF14-driven ERK/JNK/NF-κB activation; downregulate TNFSF14 receptor expression on target cells. In Vitro. This is the only published direct-modulation data for any compound currently in the Open Enzyme supplement stack. Upgrades EGCG's chokepoint profile from CP1/CP4/CP5 to CP1b-direct + CP1/CP4/CP5.
  • DHA (omega-3): Huang et al. 2024 (PMID: 38235898) — Mendelian-randomization evidence that DHA levels negatively associate with circulating TNFSF14 (OR 0.933, p=0.022); TNFSF14 positively associates with atopic dermatitis risk. Human genetic / Mechanistic Extrapolation. Suggests systemic DHA intake lowers serum LIGHT.
  • Vitamin D: Faienza et al. 2023 (PMID: 36917420) — inverse correlation of serum LIGHT with 25(OH)D in Prader-Willi. Observational / correlational. Mechanistic Extrapolation.
  • Liraglutide (GLP-1): Grannes et al. 2024 (PMID: 38685051) — significantly reduces circulating LIGHT after 16 weeks of treatment in obese/T2D vs. matched-weight-loss lifestyle controls. Clinical Trial. Not in the stack but relevant for metabolic-gout comorbidity.

No direct TNFSF14 data for

Curcumin, resveratrol, berberine, sulforaphane, oridonin, andrographolide, parthenolide, quercetin, spermidine, trehalose, MitoQ, NAC, colchicine, BHB, KPV, BPC-157, TB-500. All are plausible indirect modulators (via NF-κB suppression, which would reduce TNFSF14 transcription and LIGHT-driven NF-κB output simultaneously), but published direct data are absent. This is a testable screening gap.

5. Genetics

Zuccala et al. 2021 J Genet Genomics (PMID: 34353742) — fine-mapping in Italian multiple sclerosis shows the intronic SNP rs1077667 is the primary MS-associated TNFSF14 variant, with the risk allele driving reduced TNFSF14 mRNA in blood cells but increased LIGHT+ myeloid DCs. Relevant as proof that TNFSF14 expression is under polymorphic control in humans and that reduced expression is disease-relevant. The Ea paper's SNP observations in gout flare are consistent with this functional genetics.

6. Placement in the NLRP3 Exploit Map

TNFSF14 is added to Chokepoint 1 as sub-branch CP1b — a myeloid amplifier loop alongside CP1a (LPS/DAMP/TLR priming). It does not justify a new CP0 (there is nothing upstream of CP1a that TNFSF14 attacks), nor a fully parallel cascade (its signaling collapses into NF-κB, the existing CP1 target).

Accessible intervention ranking:

  1. EGCG (stack) — in vitro direct receptor and IL-6 suppression. Cheap, already in stack.
  2. DHA/EPA omega-3 (stack) — human-genetic association with lower LIGHT.
  3. CERC-002 — phase-2-positive in ARDS; requires investigator-initiated trial or compassionate use to reach a gout patient. Not realistic for the current phase of Open Enzyme.
  4. Screen the rest of the stack against TNFSF14-driven IL-6 in a simple HGF or THP-1 assay — low cost, high information value. Any NF-κB blocker that also suppresses TNFSF14-driven output picks up a free CP1b justification.

7. Safety caveat

LIGHT has dual pro-inflammatory and resolution roles. Krause 2014 (PMID: 24560868) and Giles 2018 (PMID: 30524422) show LIGHT-null mice have worse DSS colitis — LIGHT is required for resolution of intestinal inflammation. Mousa 2025 review (PMID: 41030453) frames this as dual-receptor biology: HVEM engagement can be regulatory (via BTLA), LTβR engagement is the pro-inflammatory/pro-fibrotic arm. Implication: total systemic TNFSF14 blockade may trade gout-flare suppression for impaired gut/colitis resolution. Episodic flare-phase blockade or receptor-selective (LTβR-biased) inhibition is the safer design space.

8. Open questions / next actions

  • Retrieve the Ea 2024 PDF and extract N per cohort, statistical thresholds, and the myeloid cell subset identified as the joint-local TNFSF14 source.
  • Screen the existing Open Enzyme supplement stack against TNFSF14-driven IL-6 in a human macrophage (THP-1) or synoviocyte assay. One plate, 10 compounds, clear readout.
  • Contact Joosten / Radboud group (already connected via dapansutrile Phase 2a sample set) — they have the cohort infrastructure to test CERC-002 or any upstream compound against gout flare cytokines.
  • Update nlrp3-exploit-map.md, nlrp3-inflammasome.md, gout-pathophysiology.md, supplements-stack.md (EGCG/omega-3 CP1b annotation), and GRAPH.md (new TNFSF14 → HVEM/LTβR → NF-κB → priming edges).